{
  "id": 11091056,
  "title": "Would homegrown LEN cost more? Why SA should still make the HIV prevention jab",
  "url": "https://urgent.news/2026/10/01/would-homegrown-len-cost-more-why-sa-should-still-make-the-hiv",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T02:30:00.000Z",
  "source": {
    "name": "Bhekisisa",
    "slug": "bhekisisa",
    "url": "https://bhekisisa.org/opinion/2026-10-01-would-homegrown-len-cost-more-why-sa-should-still-make-the-hiv-prevention-jab/"
  },
  "original_language": "en",
  "account": "South Africa is considering three local manufacturers to potentially produce the six-monthly HIV prevention jab lenacapavir. However, it will take time and cheaper generic versions are expected from 2027. The question is whether local manufacturing can help improve access while also making the jab cheaper. The Aurum Institute's Vinodh Aroon Edward explains that the answer depends on price, guaranteed buyers, and what local manufacturers are allowed to make.",
  "summary": "South Africa wants to make the six-monthly HIV prevention injection lenacapavir locally. But cheaper generics made elsewhere are expected from 2027. Vinodh Aroon Edward explains why getting the jab to people quickly must come first — while South Africa builds the skills to make it here. The post Would homegrown LEN cost more? Why SA should still make the HIV prevention jab appeared first on…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}